{"id":46145,"date":"2025-11-08T14:45:04","date_gmt":"2025-11-08T06:45:04","guid":{"rendered":"https:\/\/flcube.com\/?p=46145"},"modified":"2025-11-08T14:45:05","modified_gmt":"2025-11-08T06:45:05","slug":"eisai-china-partners-with-shanghai-pharmaceuticals-holding-focus-on-oncology-neuroscience-and-sleep-disorders","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46145","title":{"rendered":"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders"},"content":{"rendered":"\n<p>In a high\u2011profile signing at the 8th China International Import Expo (CIIE), <strong>Eisai China<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4523:TYO\">TYO: 4523<\/a>) and <strong>Shanghai Pharmaceuticals Holding (SPH, <a href=\"https:\/\/www.google.com\/finance\/quote\/2607:HKG\">HKG: 2607<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/601607:SHA\">SHA: 601607<\/a>)<\/strong> announced a strategic cooperation agreement. The collaboration is set to accelerate the commercialization of Eisai China\u2019s innovatively\u2011developed drugs across key therapeutic areas\u2014oncology, neuroscience and sleep disorders\u2014by leveraging SPH\u2019s extensive national supply\u2011chain network and lifecycle\u2011management capabilities.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-objectives\">Strategic Objectives<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Priorities<\/strong> \u2013<\/li>\n\n\n\n<li><strong>Oncology<\/strong><\/li>\n\n\n\n<li><strong>Neuroscience<\/strong> (neuro\u2011degenerative &amp; neuro\u2011psychiatric conditions)<\/li>\n\n\n\n<li><strong>Sleep Disorders<\/strong> (insomnia &amp; related disorders)<\/li>\n\n\n\n<li><strong>Joint Value Proposition<\/strong> \u2013 Accelerate market introduction, broaden patient reach, and align commercial success with social responsibility.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-leveraging-complementary-strengths\">Leveraging Complementary Strengths<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Eisai China<\/th><th>Shanghai Pharmaceuticals Holding<\/th><\/tr><\/thead><tbody><tr><td>Global R&amp;D pipeline spanning multiple disease areas<\/td><td>Nationwide pharmaceutical supply\u2011chain network<\/td><\/tr><tr><td>Innovative drug portfolio (oncology, neuroscience, sleep)<\/td><td>Full\u2011lifecycle services for novel drugs (development to commercialization)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The alliance will co\u2011create a <strong>safe, efficient, and accessible integrated drug supply system<\/strong> that marries Eisai China\u2019s R&amp;D prowess with SPH\u2019s logistical reach. The goal is to allow global innovative breakthroughs to benefit a wider spectrum of Chinese patients while generating tangible commercial value.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a high\u2011profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46146,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[106,350,890,891,196,1151],"class_list":["post-46145","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-academic-conference","tag-eisai","tag-hkg-2607","tag-sha-601607","tag-shanghai-pharmaceuticals","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"In a high\u2011profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO: 4523) and Shanghai Pharmaceuticals Holding (SPH, HKG: 2607, SHA: 601607) announced a strategic cooperation agreement. The collaboration is set to accelerate the commercialization of Eisai China\u2019s innovatively\u2011developed drugs across key therapeutic areas\u2014oncology, neuroscience and sleep disorders\u2014by leveraging SPH\u2019s extensive national supply\u2011chain network and lifecycle\u2011management capabilities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46145\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders\" \/>\n<meta property=\"og:description\" content=\"In a high\u2011profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO: 4523) and Shanghai Pharmaceuticals Holding (SPH, HKG: 2607, SHA: 601607) announced a strategic cooperation agreement. The collaboration is set to accelerate the commercialization of Eisai China\u2019s innovatively\u2011developed drugs across key therapeutic areas\u2014oncology, neuroscience and sleep disorders\u2014by leveraging SPH\u2019s extensive national supply\u2011chain network and lifecycle\u2011management capabilities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46145\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-08T06:45:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-08T06:45:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0805.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders\",\"datePublished\":\"2025-11-08T06:45:04+00:00\",\"dateModified\":\"2025-11-08T06:45:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0805.webp\",\"keywords\":[\"Academic conference\",\"Eisai\",\"HKG: 2607\",\"SHA: 601607\",\"Shanghai Pharmaceuticals\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46145#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46145\",\"name\":\"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0805.webp\",\"datePublished\":\"2025-11-08T06:45:04+00:00\",\"dateModified\":\"2025-11-08T06:45:05+00:00\",\"description\":\"In a high\u2011profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO: 4523) and Shanghai Pharmaceuticals Holding (SPH, HKG: 2607, SHA: 601607) announced a strategic cooperation agreement. The collaboration is set to accelerate the commercialization of Eisai China\u2019s innovatively\u2011developed drugs across key therapeutic areas\u2014oncology, neuroscience and sleep disorders\u2014by leveraging SPH\u2019s extensive national supply\u2011chain network and lifecycle\u2011management capabilities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46145\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0805.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0805.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46145#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders - Insight, China&#039;s Pharmaceutical Industry","description":"In a high\u2011profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO: 4523) and Shanghai Pharmaceuticals Holding (SPH, HKG: 2607, SHA: 601607) announced a strategic cooperation agreement. The collaboration is set to accelerate the commercialization of Eisai China\u2019s innovatively\u2011developed drugs across key therapeutic areas\u2014oncology, neuroscience and sleep disorders\u2014by leveraging SPH\u2019s extensive national supply\u2011chain network and lifecycle\u2011management capabilities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46145","og_locale":"en_US","og_type":"article","og_title":"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders","og_description":"In a high\u2011profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO: 4523) and Shanghai Pharmaceuticals Holding (SPH, HKG: 2607, SHA: 601607) announced a strategic cooperation agreement. The collaboration is set to accelerate the commercialization of Eisai China\u2019s innovatively\u2011developed drugs across key therapeutic areas\u2014oncology, neuroscience and sleep disorders\u2014by leveraging SPH\u2019s extensive national supply\u2011chain network and lifecycle\u2011management capabilities.","og_url":"https:\/\/flcube.com\/?p=46145","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-08T06:45:04+00:00","article_modified_time":"2025-11-08T06:45:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0805.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46145#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46145"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders","datePublished":"2025-11-08T06:45:04+00:00","dateModified":"2025-11-08T06:45:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46145"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46145#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0805.webp","keywords":["Academic conference","Eisai","HKG: 2607","SHA: 601607","Shanghai Pharmaceuticals","TYO: 4523"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46145#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46145","url":"https:\/\/flcube.com\/?p=46145","name":"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46145#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46145#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0805.webp","datePublished":"2025-11-08T06:45:04+00:00","dateModified":"2025-11-08T06:45:05+00:00","description":"In a high\u2011profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO: 4523) and Shanghai Pharmaceuticals Holding (SPH, HKG: 2607, SHA: 601607) announced a strategic cooperation agreement. The collaboration is set to accelerate the commercialization of Eisai China\u2019s innovatively\u2011developed drugs across key therapeutic areas\u2014oncology, neuroscience and sleep disorders\u2014by leveraging SPH\u2019s extensive national supply\u2011chain network and lifecycle\u2011management capabilities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46145#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46145"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46145#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0805.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0805.webp","width":1080,"height":608,"caption":"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46145#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai China Partners with Shanghai Pharmaceuticals Holding \u2013 Focus on Oncology, Neuroscience and Sleep Disorders"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0805.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46145"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46145\/revisions"}],"predecessor-version":[{"id":46147,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46145\/revisions\/46147"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46146"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}